Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients
Preclinical and early clinical data showing the safety and potential therapeutic activity of rodatristat ethyl support its progression into Phase 2 trials in patients with pulmonary arterial hypertension (PAH). The most recent findings on Altavant Sciences’ lead therapy candidate were presented at the recent 13th Annual World…
